Triglyceride

An apple cider vinegar drink a day? New study shows it might help weight loss

Retrieved on: 
Wednesday, March 13, 2024

An experimental study, released today, looks into whether apple cider vinegar could be effective for weight loss, reduce blood glucose levels and reduce blood lipids (cholesterol and triglycerides).

Key Points: 
  • An experimental study, released today, looks into whether apple cider vinegar could be effective for weight loss, reduce blood glucose levels and reduce blood lipids (cholesterol and triglycerides).
  • The results suggest it could reduce all three – but it might not be as simple as downing an apple cider vinegar drink a day.

What did they do?

  • A control group consumed an inactive drink (a placebo) made (from lactic acid added to water) to look and taste the same.
  • The study was also double-blinded, which means neither the participants or the scientists involved with collecting the data knew who was in which group.

So, what did they find?

  • After a period of three months apple cider vinegar consumption was linked with significant falls in body weight and body mass index (BMI).
  • On average, those who drank apple cider vinegar during that period lost 6–8kg in weight and reduced their BMI by 2.7–3 points, depending on the dose.
  • The authors also report significant decreases in levels of blood glucose, triglycerides, and cholesterol in the apple cider groups.

Is this good news?

  • Firstly, study participants were aged from 12 to 25, so we can’t say whether the results could apply to everyone.
  • And while the researchers kept records of the participants’ diet and exercise during the study, these were not published in the paper.
  • This could be important and influence results if people who did not lose weight quit due to lack of motivation.


Read more:
Turns out the viral 'Sleepy Girl Mocktail' is backed by science. Should you try it?

Any other concerns?


Apple cider vinegar is acidic and there are concerns it may erode tooth enamel. This can be a problem with any acidic beverages, including fizzy drinks, lemon water and orange juice. To minimise the risk of acid erosion some dentists recommend the following after drinking acidic drinks:

Read more:
Apple cider vinegar: is drinking this popular home remedy bad for your teeth? A dentist explains

Down the hatch?

  • This study provides us with some evidence of a link between apple cider vinegar and weight loss.
  • This would provide more robust evidence that apple cider vinegar could be a useful aid for weight loss.


Evangeline Mantzioris is affiliated with Alliance for Research in Nutrition, Exercise and Activity (ARENA) at the University of South Australia. Evangeline Mantzioris has received funding from the National Health and Medical Research Council, and has been appointed to the National Health and Medical Research Council Dietary Guideline Expert Committee.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

WAYLIVRA (volanesorsen): An Antisense Oligonucleotide Inhibitor of Apolipoprotein CIII (apoCIII) mRNA - Market Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.
  • WAYLIVRA (volanesorsen), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics to treat familial partial lipodystrophy (FPL).
  • Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation and preventing the translation of apoC-III protein.
  • What are the other emerging products available and how are these giving competition to WAYLIVRA for lipodystrophy?

The BioCollective® Awarded Groundbreaking Probiotic Patent

Retrieved on: 
Thursday, March 7, 2024

DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.

Key Points: 
  • The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
  • The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
  • The US Patent and Trademark Office issued US Patent No.
  • The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.

Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says

Retrieved on: 
Thursday, February 29, 2024

LONG BEACH, Calif., Feb. 29, 2024 /PRNewswire/ -- As reported in today's issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with a simple blood test.

Key Points: 
  • "Pancreatic cancer is the third leading cause of death from cancer largely because it is rarely caught early," said Dr. Robert Nagourney, senior author.
  • Using Mass Spectrometry to measure minute concentrations of bio-chemicals in the plasma, the technique identified pancreatic cancer in the blood with near perfect accuracy.
  • The results provide a "cancer signature" that distinguishes patients with pancreatic cancer from normal individuals and can distinguish pancreatic cancer from other forms of cancer, like breast and ovarian.
  • Following Genomics, the study of DNA and Proteomics, the study of cell proteins, metabolomics, is the new "omic" to watch.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

New Research: Eating Almonds Can Aid in Post-Exercise Recovery

Retrieved on: 
Wednesday, February 21, 2024

MODESTO, Calif., Feb. 21, 2024 /PRNewswire/ -- A new study found that eating almonds reduced some feelings of muscle soreness during exercise recovery which translated to improved muscle performance during a vertical jump challenge. These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.

Key Points: 
  • These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.
  • The treadmill test was designed to cause muscle damage to see how almonds affected muscle recovery.
  • Study Conclusion: Snacking on almonds for eight weeks reduced perceived feelings of muscle soreness during recovery from muscle-damaging exercise, resulting in better maintenance of muscle functional capacity.
  • This study suggests that almonds are a functional food snack to improve exercise tolerance in mildly overweight, middle-aged adults.

New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils

Retrieved on: 
Thursday, February 15, 2024

HOUSTON, Feb. 15, 2024 /PRNewswire/ -- Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) by up to 25%.1,2  "This marks the second clinical trial endorsing the use of AlmegaPL® algal lecithin to support cardiovascular health in a generally healthy population," says Dr. Eneko Ganuza, a principal investigator who led the research.

Key Points: 
  • The new clinical trial led by Dr. Ganuza and sponsored by Qualitas Health was initiated to uncover just how effective an over-the-counter supplement can be in supporting cardiovascular health in the real-world population.
  • The findings support existing beliefs that EPA-only omega-3s like AlmegaPL® could provide greater cardiovascular benefits when compared to traditional sources of omega-3s like fish and krill oil that contain both EPA and DHA.
  • This highlights the use of naturally sourced AlmegaPL® algal oil as an over-the-counter supplement to help support cardiovascular health in the general healthy population."
  • There is something about the unique polar form in which this algal lecithin yields the omega-3s that prove highly beneficial to our heart health."

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

How much weight do you actually need to lose? It might be a lot less than you think

Retrieved on: 
Monday, February 5, 2024

But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.

Key Points: 
  • But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.
  • They’ll typically use a body mass index (BMI) calculator to confirm a “healthy” weight and provide a goal weight based on this range.
  • Most sales pitches will suggest you need to lose substantial amounts of weight to be healthy – making weight loss seem an impossible task.

Using BMI to define our target weight is flawed

  • So it’s no surprise we use measurements and equations to score our weight.
  • BMI classifies bodies as underweight, normal (healthy) weight, overweight or obese and can be a useful tool for weight and health screening.


fails to consider two critical factors related to body weight and health – body fat percentage and distribution
does not account for significant differences in body composition based on gender, ethnicity and age.

How does losing weight benefit our health?

  • Losing just 5–10% of our body weight – between 6 and 12kg for someone weighing 120kg – can significantly improve our health in four key ways.
  • But research shows improvements in total cholesterol, LDL cholesterol and triglyceride levels are evident with just 5% weight loss.
  • Excess weight is linked to high blood pressure in several ways, including changing how our sympathetic nervous system, blood vessels and hormones regulate our blood pressure.
  • A meta-analysis of 25 trials on the influence of weight reduction on blood pressure also found every kilo of weight loss improved blood pressure by one point.
  • Research shows just 7% weight loss reduces risk of developing type 2 diabetes by 58%.
  • In one study each kilogram of weight loss resulted in a fourfold decrease in the load exerted on the knee in each step taken during daily activities.

Focus on long-term habits

  • An analysis of 29 long-term weight-loss studies found participants regained more than half of the weight lost within two years.
  • When we lose weight, we take our body out of its comfort zone and trigger its survival response.
  • Read more:
    What's the 'weight set point', and why does it make it so hard to keep weight off?


losing weight in small manageable chunks you can sustain, specifically periods of weight loss, followed by periods of weight maintenance, and so on, until you achieve your goal weight
making gradual changes to your lifestyle to ensure you form habits that last a lifetime.
Setting a goal to reach a healthy weight can feel daunting. But it doesn’t have to be a pre-defined weight according to a “healthy” BMI range. Losing 5–10% of our body weight will result in immediate health benefits. At the Boden Group, Charles Perkins Centre, we are studying the science of obesity and running clinical trials for weight loss. You can register here to express your interest.
Dr Nick Fuller works for the University of Sydney and has received external funding for projects relating to the treatment of overweight and obesity. He is the author and founder of the Interval Weight Loss program.